Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia

The dopamine D3 receptor, a quarter century later

(2016) Pierre Sokoloff et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology

(2015) Leonel E. Rojo et al.   PHARMACOLOGICAL RESEARCH

Initial Severity of Schizophrenia and Efficacy of Antipsychotics

(2015) Toshi A. Furukawa et al.   JAMA Psychiatry

Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment

(2014) Mark J. Millan et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Determinants of Antipsychotic Response in Schizophrenia

(2014) Jonathan Rabinowitz et al.   JOURNAL OF CLINICAL PSYCHIATRY

The potential role of dopamine D3 receptor neurotransmission in cognition

(2013) Shinichiro Nakajima et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia

(2012) R.S. Wallwork et al.   SCHIZOPHRENIA RESEARCH

Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties

(2011) Adrian Newman-Tancredi et al.   PSYCHOPHARMACOLOGY

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

(2008) Stefan Leucht et al.   LANCET